Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection

Pediatric Infectious Disease Journal

Volumn 23, Issue 6, 2004, Pages 504-510

  Lang, Alois B ^a   Rüdeberg, Anna ^b   Schöni, Martin H ^b   Que, John U ^a   Fürer, Emil ^a   Schaad, Urs B ^c  

^a Berna Biotech AG   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Body weight; Chronic lung infection; Conjugate vaccine; Cystic fibrosis; Pseudomonas aeruginosa; Pulmonary function; Vaccination

Indexed keywords

PSEUDOMONAS VACCINE;

ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DETERIORATION; DRUG SAFETY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; LUNG FUNCTION; MALE; MORBIDITY; MORTALITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNDERWEIGHT; VACCINATION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; BACTERIAL VACCINES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HUMANS; INCIDENCE; MALE; PNEUMONIA, BACTERIAL; PROBABILITY; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; REFERENCE VALUES; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SWITZERLAND; TIME FACTORS; VACCINATION; VACCINES, CONJUGATE;

EID: 3042638668     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000129688.50588.ac     Document Type: Article

References (30)

1. Koch C, Høiby N. Pathogenesis of cystic fibrosis. Lancet. 1993;341: 1065-1069.
2. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev. 2002;15:194-222.
3. de Jong W, Kaptein AA, van der Schans CP, et al. Quality of life in patients with cystic fibrosis. Pediatr Pulmonol. 1997;23:95-100.
4. Schaad UB, Lang AB, Wedgwood J, et al. Pseudomonas aeruginosa polyvalent conjugate A vaccine in cystic fibrosis. Lancet. 1991;338: 1236-1237.
5. Cryz SJ, Wedgwood J, Lang AB, et al. Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa. J Infect Dis. 1994;169:1159-1162.
6. Lang AB, Schaad UB, Rüdeberg A, et al. Effect of high affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunisation on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Pediatr. 1995;127:711-717.
7. Doring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000;16:749-767.
8. Johansen HK, Kovesi TA, Koch C, Corey M, Høiby N, Levison H. Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen. Pediatr Pulmonol. 1998;26:89-96.
9. Polgar G, Promadsat V, eds. Pulmonary Function Testing in Children. Philadelphia, PA: WB Saunders, 1971.
10. Kraemer R, Rüdeberg A, Hadorn B, Rossi E. Relative underweight in cystic fibrosis and its prognostic value. Acta Paediatr Scand. 1978;67: 33-37.
11. Parad RB, Gerard CJ, Zurakowski D, Nichols DP, Pier GB. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun. 1999;67:4744-4750.
12. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature. 2000;407:762-764.
13. Cheng K, Smyth RL, Govan JR, et al. Spread of β-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet. 1996;348: 639-642.
14. Jones AM, Govan JR, Doherty CJ, et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet. 2001;358:557-558.
15. McCallum SJ, Corkill J, Gallagher M, Ledson MJ, Hart CA, Walshaw MJ. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P. aeruginosa. Lancet. 2001;358:558-560.
16. Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR, Johnson CA. Patterns of medical practice in cystic fibrosis, I: evaluation and monitoring of health status of patients. Pediatr Pulmonol. 1999;28:242-247.
17. Pedersen SS, Hoiby N, Espersen F, Koch C. Role of alginate in infection with with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax. 1992;47:6-13.
18. Schaad UB, Lang AB, Wedgwood J, Buehlmann U, Fuerer E. Serotype-specific serum IgG antibodies to lipopolysaccharides of Pseudomonas aeruginosa in cystic fibrosis: correlation to disease, subclass distribution, and experimental protective capacity. Pediatr Res. 1990;27:508-513.
19. Fomsgaard A, Hoiby N, Shand GH, Conrad RS, Galanos C. Longitudinal study of antibody response to lipopolysaccharides during chronic Pseudomonas aeruginosa infection in cystic fibrosis. Infect Immun. 1988;27:2270-2278.
20. Koch C. Early infection and progression of cystic fibrosis lung disease. Pediatr Pulmonol. 2002;34:232-236.
21. Tummler B, Bosshammer J, Breitenstein S, et al. Infections with Pseudomonas aeruginosa in patients with cystic fibrosis. Behring Inst Mitt. 1997;98:249-255.
22. Morgan WJ, Butler SM, Johnson CA, et al. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U. S. and Canada. Pediatr Pulmonol. 1999;28:231-241.
23. McCaffery K, Olver RE, Franklin M, Mukhopadhyay S. Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis. Thorax. 1999;54:380-383.
24. Navarro J, Rainisio M, Harms HK, et al. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF: European Epidemiologic Registry of Cystic Fibrosis. Eur Respir J. 2001;18:298-305.
25. Govan JR, Doherty C, Glass S. Rational parameter for antibiotic therapy in patients with cystic fibrosis. Infection. 1987;15:300-307.
26. Mahenthiralingam E, Baldwin A, Vandamme P. Burkholderia cepacia complex infection in patients with cystic fibrosis. J Med Microbiol. 2002;51:533-538.
27. Hutchison ML, Govan JR. Pathogenicity of microbes associated with cystic fibrosis. Microbes Infect. 1999;1:1005-1014.
28. Rajan S, Saiman L. Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect. 2002;17:47-56.
29. Graff GR, Burns JL. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest 2002;121:1754-1760.
30. Steinkamp G, Wiedemann B. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax. 2002;57:596-601.